respectively. The most common injection site reactions wereerythema, pain, and bruising. The proportions of patients who discontinued treatment due to local injection site reactions in REPATHA-treated patients and placebo-treated patients were 0.1% and 0%, respectively. ...
Adverse Reactions in Primary Hyperlipidemia:The most common adverse reactions (>5% of patients treated with Repatha®and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions. ...
The article reports that the Repatha injection, a parenteral proprotein convertase subtilisin kexin type 9 inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the management of hypercholesterolemia inadequately treated with standard lipid-lowering therapy....
57个抗体药物说明书repatha.pdf,BLA 125522 to firm 08 27 HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE FORMS AND STRENGTHS These highlights do not include all the information needed to use • Injection: 140 mg/mL in a single-use prefilled syringe (3)
美国上市药品目录集提供Repatha的基本信息,包括Repatha的申请号125522,申请类型,活性成分Evolocumab,中文名称依洛尤单抗,申请机构,批准日期等药品信息,更多美国药品Repatha的信息查询就在戊戌数据美国上市药品数据库.
依洛尤单抗重组皮下自动注射器(Repatha subcutaneous)[/caption] 新一代降脂药Repatha(Evolocumab[Genetical Recombination],中文译名:依洛尤单抗,レパーサ皮下注)用于家族性高胆固醇血症(FH)患者,以及伴有高风险心血管事件并对HMG-CoA还原酶抑制剂(他汀类药物)反应不足的高胆固醇血症患者。在日本,Repatha由安进与...
The most common side effects of Repatha®include: runny nose, sore throat, symptoms of the common cold, flu or flu-like symptoms, back pain, high blood sugar levels (diabetes) and redness, pain, or bruising at the injection site. ...
With a SureClick autoinjector or a prefilled syringe, you may take up to 15 seconds to inject the medicine. If you have to use more than one injection at a time, be sure to finish all of them in no more than 30 minutes. The Pushtronex on-body infusor is a special hands-free devi...
Learn how Repatha®, a PCSK9 inhibitor, can reduce the risk of myocardial infarction, stroke or coronary revascularization in your patients with established CVD.